Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 1
2007 2
2008 3
2009 8
2010 13
2011 8
2012 13
2013 25
2014 20
2015 10
2016 18
2017 36
2018 28
2019 31
2020 48
2021 57
2022 53
2023 33
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Editorial Comment.
Hatakeyama S, Hamano I, Ohyama C. Hatakeyama S, et al. J Urol. 2021 Jan;205(1):107. doi: 10.1097/JU.0000000000001325.01. Epub 2020 Oct 23. J Urol. 2021. PMID: 33095100 No abstract available.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Fertility preservation of patients with testicular cancer.
Hamano I, Hatakeyama S, Ohyama C. Hamano I, et al. Among authors: hatakeyama s. Reprod Med Biol. 2017 May 18;16(3):240-251. doi: 10.1002/rmb2.12037. eCollection 2017 Jul. Reprod Med Biol. 2017. PMID: 29259474 Free PMC article. Review.
Editorial Comment.
Hatakeyama S, Imai A, Ohyama C. Hatakeyama S, et al. J Urol. 2019 Aug;202(2):359-360. doi: 10.1097/01.JU.0000559824.07845.4c. Epub 2019 Jul 8. J Urol. 2019. PMID: 31095466 No abstract available.
Tumor formation assays.
Hatakeyama S, Yamamoto H, Ohyama C. Hatakeyama S, et al. Methods Enzymol. 2010;479:397-411. doi: 10.1016/S0076-6879(10)79023-6. Methods Enzymol. 2010. PMID: 20816179
353 results